General Information of Drug (ID: DMRAXD1)

Drug Name
PMID26560530-Compound-7 Drug Info
Cross-matching ID
PubChem CID
6193963
TTD Drug ID
DMRAXD1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ZED1227 DMDXEN5 Coeliac disease DA95 Phase 2 [2]
PMID26560530-Compound-13 DMKF26Z N. A. N. A. Patented [1]
PMID26560530-Compound-54 DM2X4R0 N. A. N. A. Patented [1]
Triazole derivative 1 DM9QB2S N. A. N. A. Patented [1]
Acyl piperidine derivative 3 DMIDUB4 N. A. N. A. Patented [1]
PMID26560530-Compound-14 DM52MIK N. A. N. A. Patented [1]
PMID26560530-Compound-1 DMSI7F2 N. A. N. A. Patented [1]
PMID26560530-Compound-3 DM92OT0 N. A. N. A. Patented [1]
PMID26560530-Compound-11 DMZ5UST N. A. N. A. Patented [1]
Chloroacetyl ester derivative 1 DMW4J0P N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tissue transglutaminase (TG2) TT2F4OL TGM2_HUMAN Inhibitor [1]

References

1 Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63.
2 Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease. Cells. 2022 May 17;11(10):1667.